)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Genscript Biotech
Genscript Biotech (1548) investor relations material
Genscript Biotech H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary16 Aug, 2026
Executive summary
Revenue for the first half of 2026 reached $404.2 million, up 27.3% year-over-year, with adjusted net profit surging 203.3% to $62.5 million; core business net profit rose 116.7% to $25.6 million, while reported net loss narrowed to $129.3 million due to equity accounting impacts from Legend Group.
Growth was driven by AI-driven demand, expansion of the gene-to-protein platform, and operational efficiency gains across all business segments.
The company is positioned as a critical infrastructure provider for AI-enabled biotech innovation, with a diversified global customer base and strong balance sheet.
Operating leverage, innovation, and global expansion accelerated profitability and margin expansion.
Three main business segments: Life Science Group (78% of revenue), ProBio (14.4%), and Bestzyme (7.5%).
Financial highlights
Group revenue reached $404.2 million, up 27.3% year-over-year; gross profit was $206.7 million, up 48%.
Adjusted net profit hit $62.5 million, up 203.3% year-over-year; net loss was $129.3 million, improved from $181.9 million loss.
Life Science Group revenue grew 28.8% to $319 million; ProBio revenue rose 34.2% to $61.1 million; Bestzyme revenue increased 7.4% to $30.4 million.
Adjusted gross margin for Life Science Group reached 57.8% (55.4% excluding U.S. tariff refunds); adjusted operating margin was 29.5% (27.1% excluding refunds).
Loss per share: (5.92) US cents.
Outlook and guidance
Full-year guidance for Life Science Service segment raised: revenue growth expected at 25%-30%, adjusted gross margin above 55%, and adjusted operating margin above 25%.
ProBio revenue growth guidance increased to 25%-30%, with positive EBITDA targeted for 2027.
Bestzyme expected to achieve 8%-10% revenue growth and maintain adjusted gross margin over 43%.
Continued strategic investments in gene-to-protein platform, automation, and digitalization to support AI-driven drug discovery.
Sufficient resources and liquidity to support planned capital investments.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Genscript Biotech
- Revenue rose 34.2%, led by CARVYKTI growth, while adjusted losses persisted.1548
H2 2023 - Revenue up 61.4% to $959.5M, adjusted net profit up 285%, but net loss from Legend impairment.1548H2 2025
- Pursuing global leadership in life sciences with high-margin growth, innovation, and digitalization.1548Investor Day 2025 Presentation
- Revenue up 81.9% to $518.8M, adjusted net profit up 509.6%, strong license-driven growth.1548H1 2025
- Revenue up 43.5% to $561.4M, driven by cell therapy and Bestzyme; adjusted net loss narrowed.1548H1 2024
- Net profit soared to $2.9B on a $3.2B gain from cell therapy business deconsolidation.1548H2 2024
Next Genscript Biotech earnings date
H2 202614 Mar, 2027
Genscript Biotech
Next Genscript Biotech earnings date
H2 202614 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
GenScript Biotech Corporation is a China-based biotechnology company specializing in life sciences services and products. The company provides a wide range of solutions, including gene synthesis, peptide synthesis, antibody development, and protein engineering. GenScript serves customers in sectors such as pharmaceuticals, agriculture, and industrial biotechnology. The company is headquartered in Nanjing, China, and its shares are listed on the Hong Kong Stock Exchange.